Overview

Daniel is an Associate (Foreign Qualified) in the Corporate Practice. He has extensive experience leading clients through all aspects of complex corporate and commercial transactions across the technology, consumer goods and retail, life sciences, and agri-tech sectors. His practice includes:

  • Representing public and private companies in cross-border M&A transactions.
  • Advising venture capital funds and emerging growth companies on the full spectrum of early-stage investments and fundraisings, as well as on their day-to-day legal needs.
  • Advising global private equity clients on the acquisition and disposal of portfolio companies.

In addition to his transactional work, Daniel has experience advising large multinational corporations on joint ventures, global restructurings and franchising.

Experience

Daniel graduated with law and finance degrees from the University of Otago. Prior to joining Caldwell, he worked as a corporate associate at global law firm, DLA Piper.

Daniel enjoys working with innovative companies. His clients have ranged from small startups to some of the world’s largest and most well-known brands.

Daniel’s experience includes:

  • Advising Finistere Ventures on its seed investment in Scentian Bio, a New Zealand novel technology start up that harnesses smell receptors from insects with the goal of biosensing volatiles in food and human diseases;
  • Advising a New Zealand based digital effects company on the sale of its VFX business to a NYSE listed US acquirer for $1.625 billion;
  • Advising a large US-based private equity firm on its acquisition of a majority stake in an APAC technology procurement company;
  • Advising a San Francisco based venture firm on its series A and subsequent series A-3 investments in an early-stage technology start-up;
  • Advising a San Francisco based venture firm on its series C investment in New Zealand agri-tech unicorn, Halter, Inc;
  • Acting as key external legal advisor to New Zealand’s largest retail grocer and its second largest organization, including advising on over 100 of its franchisee and change of ownership transactions;
  • Advising a large commercial property developer and investor, on its investment in a startup in the renewable energy sector;
  • Advising a NASDAQ listed producer of glucose monitoring systems for diabetes management, on its acquisition of two New Zealand life-science companies;
  • Advising a NYSE listed tech company on the New Zealand aspects of its strategic takeover of a global SAP consulting business, worth over $450 million; and
  • Acting on the New Zealand aspects of numerous corporate reorganizations and joint ventures by global multinationals, including the reorganization of a consumer healthcare business valued up to $20 billion globally.